BackChina Biologic Products Holdings Overview

China Biologic Products Holdings Net Tangible Assets

Latest net tangible assets for CBPO: $2.1B.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$2.08B
58.35% YoYΔ $767.10M vs prior year quarter

Peer trimmed avg / median

Loading

China Biologic Products Holdings Net Tangible Assets History

Loading

China Biologic Products Holdings vs. peers: Net Tangible Assets Comparison

Loading

China Biologic Products Holdings Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

China Biologic Products Holdings (CBPO) FAQ

China Biologic Products Holdings (CBPO) currently reports a net tangible assets of $2.1B as of December 2020. That compares with $1.3B in the prior-year period — up 58.3% year over year. Use the charts on this page to explore China Biologic Products Holdings's net tangible assets history and peer comparisons.

China Biologic Products Holdings's net tangible assets increased from $1.3B to $2.1B — a 58.3% year-over-year increase (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Biologic Products Holdings reported $2.1B in net tangible assets as of December 2020. That compares with $1.3B in the prior-year period — up 58.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $2.1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for China Biologic Products Holdings, and consider following CBPO for alerts when major investors trade the stock.

China Biologic Products Holdings is classified in the Healthcare sector. On net tangible assets, it currently shows $2.1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBPO with unrelated industries.